Group One Trading
RLMD icon

Group One Trading’s Relmada Therapeutics RLMD Stock Holding History

Group One Trading’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$584K Sell
83,900
-93,500
-53% -$442K ﹤0.01% 3201
2025
Q4 		$857K Buy
177,400
+121,600
+218% +$407K ﹤0.01% 3037
2025
Q3 		$112K Buy
55,800
+31,500
+130% +$30.2K ﹤0.01% 5228
2025
Q2 		$14.6K Sell
24,300
-48,400
-67% -$24.8K ﹤0.01% 6472
2025
Q1 		$19.6K Sell
72,700
-40,700
-36% -$13.5K ﹤0.01% 5820
2024
Q4 		$59K Sell
113,400
-47,600
-30% -$116K ﹤0.01% 4933
2024
Q3 		$522K Buy
161,000
+158,900
+7,567% +$515K ﹤0.01% 2823
2024
Q2 		$6.3K Sell
2,100
-49,300
-96% -$178K ﹤0.01% 5850
2024
Q1 		$239K Buy
51,400
+25,200
+96% +$121K ﹤0.01% 3403
2023
Q4 		$108K Buy
26,200
+21,200
+424% +$62.8K ﹤0.01% 4395
2023
Q3 		$15K Sell
5,000
-8,300
-62% -$24.7K ﹤0.01% 6100
2023
Q2 		$32.7K Sell
13,300
-7,000
-34% -$19.4K ﹤0.01% 5614
2023
Q1 		$45.9K Sell
20,300
-274,000
-93% -$945K ﹤0.01% 4914
2022
Q4 		$1.03M Sell
294,300
-152,100
-34% -$1.34M ﹤0.01% 2381
2022
Q3 		$16.5M Buy
446,400
+389,700
+687% +$10.8M 0.03% 480
2022
Q2 		$1.08M Sell
56,700
-34,200
-38% -$746K ﹤0.01% 2680
2022
Q1 		$2.45M Buy
90,900
+23,200
+34% +$480K ﹤0.01% 2204
2021
Q4 		$1.52M Sell
67,700
-100
-0.1% -$2.22K ﹤0.01% 2899
2021
Q3 		$1.78M Buy
67,800
+62,500
+1,179% +$1.67M ﹤0.01% 2789
2021
Q2 		$170K Sell
5,300
-3,300
-38% -$115K ﹤0.01% 5405
2021
Q1 		$303K Sell
8,600
-1,400
-14% -$49K ﹤0.01% 4563
2020
Q4 		$321K Sell
10,000
-2,200
-18% -$75.6K ﹤0.01% 3681
2020
Q3 		$459K Buy
12,200
+10,900
+838% +$421K ﹤0.01% 2917
2020
Q2 		$58K Buy
1,300
+1,200
+1,200% +$50.7K ﹤0.01% 4263
2020
Q1 		$3K Hold
100
– – ﹤0.01% 4903
2019
Q4 		$4K Buy
+100
New +$3.04K ﹤0.01% 4799

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Group One Trading's RLMD Position: Q1 2026 in Review

Group One Trading opened a new position in Relmada Therapeutics (RLMD) in Q1 2026: 14,350 shares worth $99.9K. The stake represents ﹤0.01% of the portfolio and ranks #4726 among its holdings. This is a return to the name: Group One Trading previously reported a position in RLMD as recently as Q2 2025.

Group One Trading first reported a position in RLMD in Q1 2021 and has held it in 16 quarters since. The position peaked at $857K in Q1 2024. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Group One Trading held 14,350 shares of Relmada Therapeutics worth $99.9K as of Q1 2026.
  • Relmada Therapeutics was a new Group One Trading position in Q1 2026.
  • Relmada Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #4726 holding.
  • Group One Trading first reported a position in Relmada Therapeutics in Q1 2021 and has held it in 16 quarters since.
  • Group One Trading's Relmada Therapeutics position peaked at $857K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.